(Promotion of Optimal Well-Being, Education and Regulation for Celiac Disease)
A FREE brand new, online, evidence-based program for people newly diagnosed and/or struggling with celiac disease. All North American adults diagnosed with celiac disease (blood test and/or biopsy) are eligible to participate. POWER-C contains 4 modules to be completed bi-weekly over the course of 8 weeks. For more information please email [email protected].
To learn more about this study, click here
Study on Refractory Celiac Disease Type II
The Celiac Center is pleased to be partnering with Celimmune, which is working hard to find a treatment for those with the most difficult cases of celiac disease. Celimmune has launched a Phase II study to test an experimental therapy for those diagnosed with Refractory Celiac Disease Type II. RCD Type II is an extremely rare form of celiac disease, with only a handful of patients diagnosed with it in the United States. Refractory celiac disease is defined as persistent or recurrent intestinal atrophy and gastrointestinal symptoms despite adherence to a strict gluten-free diet for at least 6-12 months. In addition, the presence of aberrant (precursor of cancer) intraepithelial lymphocytes (ELs) is another hallmark characteristic of refractory celiac disease. Patients with a low proportion (<20%) of aberrant IELs, as determined by flow cytometry, are diagnosed with refractory celiac disease Type I. When the aberrant IELs exceeds 20%, the patient is diagnosed with refractory celiac disease Type II. For more information, please visit www.celimmune.com
or contact [email protected]
Pilot Study of Montelukast in Celiac Disease
This is a double-blinded, placebo controlled study to assess the efficacy and safety of a study drug montelukast in celiac disease. We will evaluate the safety and effectiveness of montelukast when given to people with celiac disease. If you agree to participate in this study, you will be given the study drug, monteluklast and bread (gluten) for purposes of this study.
Montelukast has been approved by the Food and Drug Administration (FDA) for the treatment of asthma. It works by blocking the action of substances in the body that cause the symptoms of asthma and allergic rhinitis (irritation and swelling of the tissues in the nose). Montelukast controls the symptoms of asthma and allergic rhinitis but does not cure these conditions.
While montelukast is not FDA approved for the treatment of celiac disease, preliminary research shows that montelukast blocks cytotoxic T cell (a type of immune cell) that stimulates intestinal damage. Montelukast is an experimental drug in this study.
The University of Chicago Celiac Disease Center is currently conducting a research study for teenagers with celiac disease and their parents, to better understand the feelings and coping skills of our adolescent patients with celiac disease and how this affects their adherence to a gluten-free diet later in life. Our goal is to use this information to improve adherence to a gluten-free diet for these patients as they get older.